HB-EGF and Intestinal Ischemia/Reperfusion
HB-EGF 和肠缺血/再灌注
基本信息
- 批准号:8107965
- 负责人:
- 金额:$ 31.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-01-15 至 2015-05-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAllogenicBone MarrowCause of DeathCell CommunicationCell Surface ReceptorsCellsClinicalClinical TrialsCritical IllnessDTR geneDataEffectivenessElementsExposure toFunctional disorderFutureGoalsGrowth FactorHematopoietic Stem Cell MobilizationHumanInflammation MediatorsInjuryIntestinal MucosaIntestinesInvestigational TherapiesIschemiaIschemic Bowel DiseaseKnockout MiceKnowledgeLaboratoriesLeadMediatingMissionModelingMorbidity - disease rateMotorMultiple Organ FailureMultipotent Stem CellsNatural regenerationNotch Signaling PathwayOrganoidsOutcomePatientsPublic HealthReperfusion InjuryReperfusion TherapyResearchSepsis SyndromeSignal TransductionStem cellsSystemTestingTherapeutic InterventionTransgenic MiceTreatment EfficacyUnited States National Institutes of HealthVillousWorkbasebone morphogenic proteincell injuryclinical efficacydesignheparin-binding EGF-like growth factorimprovedin vivoinnovationmortalitynovelnovel therapeuticsreceptor
项目摘要
DESCRIPTION (provided by applicant): Despite decades of research, there is a fundamental gap in our understanding of how to adequately protect the intestines from the sequellae of ischemia/reperfusion (I/R) injury. We have accumulated multiple lines of evidence demonstrating that heparin-binding EGF-like growth factor (HB-EGF) can protect the intestines from I/R injury. The long-term goal of our work is to administer HB-EGF therapeutically to protect the intestines from injury. The overall objective of the current renewal application is to identify key elements of the interaction of HB- EGF with stem cells (SC) that may be utilized to augment the activity of the growth factor. Our central hypothesis is that a significant proportion of the intestinal cytoprotective effects of HB- EGF are mediated through its effects on SC, and that the interaction of HB-EGF with SC can be augmented in order to increase the efficacy of the growth factor. The rationale is that once the interactions of HB-EGF with SC are better understood, maximally beneficial innovative approaches to the treatment of intestinal I/R injury can be developed. We will objectively test our central hypothesis by pursuing the following specific aims: Aim 1) to determine the signaling mechanisms and receptors utilized by HB-EGF in protecting intestinal SC (ISC) from injury. We will use highly purified ISC to determine the effects of HB-EGF on the Wnt, BMP, PI3K and Notch signaling pathways in these cells. Aim 2) to determine whether endogenous HB-EGF expression affects ISC expansion and differentiation after injury. We will use a novel ex vivo crypt-villous organoid culture system and an in vivo intestinal I/R injury model to investigate the effects of HB-EGF on ISC expansion and differentiation. Aim 3) to determine whether bone marrow (BM)-derived SC can improve HB-EGF-mediated protection of the intestines from injury. We will determine the effects of SC mobilization or administration, in conjunction wth HB-EGF administration, in protection of the intestines from I/R injury in vivo. The results of our studies are expected to have an important positive impact in terms of providing improved therapeutic interventions for patients suffering from intestinal I/R injury, in addition to fundamentally advancing the understanding of growth factor/SC interactions in the intestines. This contribution is significant because it will enable us to best exploit the potential of clinical HB-EGF therapy. The proposed research is innovative because we seek to shift current experimental therapies for intestinal I/R injury away from the targeting of single inflammatory mediators, and towards strategies designed to protect and regenerate the intestinal mucosa, through administration of an intestinal cytoprotective growth factor in conjunction with multipotent SC.
PUBLIC HEALTH RELEVANCE: The proposed research is relevant to public health because it is expected to lead to a novel therapeutic strategy that will decrease morbidity and mortality related to intestinal I/R injury. The innovative approach to intestinal I/R injury that is proposed will lead to substantive improvements in clinical outcomes at the bedside, which is consistent with the mission of the NIH.
描述(由申请人提供):尽管进行了数十年的研究,但我们对如何充分保护肠道免受缺血/再灌注(I/R)损伤后遗症的理解存在根本性差距。我们已经积累了多条证据表明,肝素结合EGF样生长因子(HB-EGF)可以保护肠道免受I/R损伤。我们工作的长期目标是给予HB-EGF治疗,以保护肠道免受损伤。目前更新申请的总体目标是确定HB-EGF与干细胞(SC)相互作用的关键要素,这些要素可用于增强生长因子的活性。我们的中心假设是,HB-EGF的肠道细胞保护作用的显著比例是通过其对SC的作用介导的,并且HB-EGF与SC的相互作用可以增强以增加生长因子的功效。其基本原理是,一旦HB-EGF与SC的相互作用得到更好的理解,就可以开发出治疗肠I/R损伤的最有益的创新方法。我们将通过以下具体目标客观地检验我们的中心假设:目的1)确定HB-EGF在保护肠SC(ISC)免受损伤中所利用的信号传导机制和受体。我们将使用高度纯化的ISC来确定HB-EGF对这些细胞中Wnt、BMP、PI 3 K和Notch信号通路的影响。目的2)探讨内源性HB-EGF表达对损伤后ISC扩增和分化的影响。我们将使用一种新的离体隐窝-绒毛类器官培养系统和在体肠I/R损伤模型来研究HB-EGF对ISC扩增和分化的影响。目的3)研究骨髓源性SC是否能增强HB-EGF介导的肠道保护作用。我们将确定SC动员或给药与HB-EGF给药结合在体内保护肠免受I/R损伤中的作用。我们的研究结果预计将在为肠I/R损伤患者提供改善的治疗干预方面产生重要的积极影响,此外还将从根本上促进对肠道中生长因子/SC相互作用的理解。这一贡献是重要的,因为它将使我们能够最好地利用临床HB-EGF治疗的潜力。拟议的研究是创新的,因为我们寻求将目前的肠I/R损伤实验疗法从单一炎症介质的靶向转移到旨在保护和再生肠粘膜的策略,通过给予肠细胞保护生长因子与多能SC。
公共卫生相关性:这项研究与公共卫生有关,因为它有望产生一种新的治疗策略,降低与肠道I/R损伤相关的发病率和死亡率。提出的肠I/R损伤的创新方法将导致床旁临床结局的实质性改善,这与NIH的使命一致。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GAIL E BESNER其他文献
GAIL E BESNER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GAIL E BESNER', 18)}}的其他基金
A Novel Probiotic Platform to Treat Necrotizing Enterocolitis
治疗坏死性小肠结肠炎的新型益生菌平台
- 批准号:
9344825 - 财政年份:2017
- 资助金额:
$ 31.13万 - 项目类别:
Exosomes and HB-EGF in Stem Cell-Mediated Therapy for Necrotizing Enterocolitis
外泌体和 HB-EGF 在干细胞介导的坏死性小肠结肠炎治疗中的应用
- 批准号:
8993642 - 财政年份:2015
- 资助金额:
$ 31.13万 - 项目类别:
Exosomes and HB-EGF in Stem Cell-Mediated Therapy for Necrotizing Enterocolitis
外泌体和 HB-EGF 在干细胞介导的坏死性小肠结肠炎治疗中的应用
- 批准号:
9021132 - 财政年份:2015
- 资助金额:
$ 31.13万 - 项目类别:
HB-EGF Therapy for Necrotizing Entercolitis
HB-EGF 治疗坏死性小肠结肠炎
- 批准号:
7322472 - 财政年份:2007
- 资助金额:
$ 31.13万 - 项目类别:
HB-EGF Therapy for Necrotizing Entercolitis
HB-EGF 治疗坏死性小肠结肠炎
- 批准号:
7626478 - 财政年份:2007
- 资助金额:
$ 31.13万 - 项目类别:
HB-EGF Therapy for Necrotizing Entercolitis
HB-EGF 治疗坏死性小肠结肠炎
- 批准号:
8074971 - 财政年份:2007
- 资助金额:
$ 31.13万 - 项目类别:
HB-EGF Therapy for Necrotizing Entercolitis
HB-EGF 治疗坏死性小肠结肠炎
- 批准号:
7474014 - 财政年份:2007
- 资助金额:
$ 31.13万 - 项目类别:
相似海外基金
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
- 批准号:
17K10951 - 财政年份:2017
- 资助金额:
$ 31.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
- 批准号:
16K10863 - 财政年份:2016
- 资助金额:
$ 31.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Nerve regeneration through A vessel-containing nerve conduit implanted with bone marrow stromal cells and decellularized allogenic nerve matrix
通过植入骨髓基质细胞和脱细胞同种异体神经基质的含血管神经导管进行神经再生
- 批准号:
26462240 - 财政年份:2014
- 资助金额:
$ 31.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The induction of allogenic bone marrow chimerism regulates some lineage of auto-reactive lymphocite, but not all of them in lupus prone mice.
同种异体骨髓嵌合的诱导调节了自身反应性淋巴细胞的一些谱系,但不是狼疮易感小鼠中的全部谱系。
- 批准号:
24591469 - 财政年份:2012
- 资助金额:
$ 31.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanism of allogenic bone marrow therapy in epidermolysis bullosa model mice
大疱性表皮松解症模型小鼠同种异体骨髓治疗的机制
- 批准号:
24659515 - 财政年份:2012
- 资助金额:
$ 31.13万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Bystander killing effect of suicide gene-transducted allogenic bone marrow stromal cells on malignant glioma
自杀基因转导的同种异体骨髓基质细胞对恶性胶质瘤的旁观者杀伤作用
- 批准号:
19591703 - 财政年份:2007
- 资助金额:
$ 31.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CMV-SPECIFIC CELLULAR IMMUNITY IN RECIPIENTS OF ALLOGENIC BONE MARROW TRANSPLANT
同种异体骨髓移植受者的 CMV 特异性细胞免疫
- 批准号:
7603858 - 财政年份:2006
- 资助金额:
$ 31.13万 - 项目类别:
CMV-SPECIFIC CELLULAR IMMUNITY IN RECIPIENTS OF ALLOGENIC BONE MARROW TRANSPLANT
同种异体骨髓移植受者的 CMV 特异性细胞免疫
- 批准号:
7368155 - 财政年份:2005
- 资助金额:
$ 31.13万 - 项目类别:
CMV-SPECIFIC CELLULAR IMMUNITY IN RECIPIENTS OF ALLOGENIC BONE MARROW TRANSPLANT
同种异体骨髓移植受者的 CMV 特异性细胞免疫
- 批准号:
7199948 - 财政年份:2004
- 资助金额:
$ 31.13万 - 项目类别: